Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1

Annals of the New York Academy of Sciences

Volumn 1194, Issue , 2010, Pages 6-19

  Matteucci, Claudia ^a   Minutolo, Antonella ^a   Sinibaldi Vallebona, Paola ^a   Palamara, Anna Teresa ^b   Rasi, Guido ^c   Mastino, Antonio ^d   Garaci, Enrico ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

Immunomodulation; Immunotherapy; Thymic peptides; Transcriptional response

Indexed keywords

CHEMOKINE; THYMOSIN ALPHA1;

ANTIGEN RECOGNITION; CELL ACTIVITY; CONFERENCE PAPER; ENERGY METABOLISM; EXTRACELLULAR MATRIX; GENETIC TRANSCRIPTION; HLA SYSTEM; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNE SYSTEM; LYMPHOCYTE FUNCTION; MEMBRANE CHANNEL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 77951803702     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05484.x     Document Type: Conference Paper

References (57)

1. Goldstein, A.L., T.L. Low, M. McAdoo, et al. 1977. Thymosin alpha-1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc. Natl. Acad. Sci. USA 74: 725-729.
2. Goldstein, A.L. & A.L Goldstein. 2009. From lab to bedside: emerging clinical applications of thymosin alpha-1. Expert Opin. Biol. Ther. 9: 593-608.
3. Garaci, E. 2007. Thymosin alpha-1: a historical overview. Ann. N.Y. Acad. Sci. 1112: 14-20.
4. Knutsen, A.P., J.J. Freeman, K.R. Mueller, et al. 1999. Thymosinαstimulates maturation of CD34+ stem cells into CD3+CD4+ cells in an in vitro thymic epithelia organ coculturemodel. Int. J. Immunopharmacol. 21: 15-26.
5. Sztein, M.B., S.A. Serrate & A.L. Goldstein. 1986. Modulation of interleukin 2 receptor expression on normal human lymphocytes by thymic hormones. Proc. Natl. Acad. Sci. USA 83: 6107-6111.
6. Oates, K.K., M.B. Sztein & A.L. Goldstein. 1989. Mechanism of action of the thymosins: modulation of lymphokines, receptors, and T-cell differentiation antigens. Immunol. Ser. 45: 273-288.
7. Favalli, C., A. Mastino, T. Jezzi, et al. 1989. Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumorbearing mice. Int. J. Immunopharmacol. 11: 443-450.
8. Mastino, A., C. Favalli, S. Grelli, et al. 1991. Thymosinβ potentiates interleukin 2-induced cytotoxic activity in mice. Cell. Immunol. 133: 196-205.
9. Mastino,A., C. Favalli, S.Grelli, et al. 1992.Combination therapy with thymosinvαpotentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice. Int. J. Cancer 50: 493-499.
10. Rasi, G., G. Silecchia, P. Sinibaldi-Vallebona, et al. 1994. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int. J. Cancer 57: 701-705.
11. Pica, F., M. Fraschetti, C. Matteucci, et al. 1998. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemoimmunotherapy for murine B16 melanoma. Anticancer Res. 18: 3571-3578.
12. Salvati, F., G. Rasi, L. Portalone, et al. 1996. Combined treatment with thymosin-alpha 1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial. Anticancer Res. 16: 1001-1004.
13. Rasi, G., E. Terzoli, F. Izzo, et al. 2000. Combined treatment with thymosin-alpha1 and low dose interferonalpha after dacarbazine in advanced melanoma. Melanoma Res. 2: 189-192.
14. Camerini, R. 2009. A large European phase II randomized study of thymosin alpha 1, interferon, or both, in combination with dacarbazine in patients with malignant melanoma. From: The Second Symposium of Thymosins in Health and Disease, 30 September-2 October Catania, Italy.
15. Garaci, E., C. Favalli, F. Pica, et al. 2007. Thymosin alpha 1: from bench to bedside. Ann. N.Y. Acad. Sci. 1112: 225-234.
16. Rasi, G., M.G. Mutchnick, D. Di Virgilio, et al. 1996. Combination of low-dose lymphoblastoid interferon and thymosin alpha-1 therapy in the treatment of chronic hepatitis B. J. Viral Hepat. 3: 191-196. (Pubitemid 126733934)
17. Saruc,M., N. Ozden, N. Turkel, et al. 2003. Long-term outcomes of thymosin-alpha 1 and interferon alpha- 2b combination therapy in patients with hepatitis B. J. Pharm. Sci. 92: 1386-1395.
18. You, J., L. Zhuang, H.Y. Cheng, et al. 2006. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: A randomized controlled study. World J. Gastroenterol. 12: 6715-6721.
19. Rasi, G., D. Di Virgilio, M.G. Mutchnick, et al. 1996. Combination thymosin α-1 and lymphoblastoid interferon treatment in chronic hepatitis C. Gut 39: 679-683.
20. Rasi, G., P. Pierimarchi, P. Sinibaldi-Vallebona, et al. 2003. Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. Int. Immunopharmacol. 3: 1169-1176.
21. Sjogren,M.H. 2004.Thymalfasin: animmune systemenhancer for the treatment of liver disease. J. Gastroenterol. Hepatol. 19: 69-72.
22. Camerini,R., A.Ciancio, A. DeRosa&M.Rizzetto. 2007. Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C. Ann. N.Y. Acad. Sci. 1112: 368-374.
23. Garaci, E., G. Rocchi, L. Perroni, et al. 1994. Combination treatment with zidovudine, thymosin alpha 1 and interferon-alpha in human immunodeficiency virus infection. Int. J. Clin. Lab. Res. 24: 23-28.
24. Chadwick, D., J. Pido-Lopez, A. Pires, et al. 2003. A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune recostitution in HIVinfected patients with low CD4 counts taking highly active antiretroviral therapy. Clin. Exp. Immunol. 134: 477-481.
25. Ershler, W.B., S. Gravenstein & Z.S. Geloo. 2007. Thymosin alpha 1 as an adjunct to influenza vaccination in the elderly: rationale and trial summaries. Ann. N.Y. Acad. Sci. 1112: 375-384.
26. Romani, L., F. Bistoni, C. Montagnoli, et al. 2007. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann. N.Y. Acad. Sci. 1112: 326-338.
27. Garaci, E., F. Pica, P. Sinibaldi-Vallebona, et al. 2003. Thymosin alpha-1 in combination with cytokines and chemotherapy for the treatment of cancer. Int. Immunopharmacol. 3: 1145-1150.
28. Sodhi, A. & S. Paul. 2002. Involvement of mitogenactivated protein kinases in the signal transduction pathway of bone marrow-derived macrophage activation in response to in vitro treatment with thymosin alpha 1. Int. Immunopharmacol. 2: 47-58.
29. Yao, Q., L.X. Doan, R. Zhang, et al. 2007. Thymosinalpha1 modulates dendritic cell differentiation and functional maturation fromhuman peripheral blood CD14+ monocytes. Immunol. Lett. 110: 110-120.
30. Peng, X., P. Zhang, X. Wang, et al. 2007. Signaling pathways leading to the activation of IKK and MAPK by thymosin alpha1. Ann. N.Y. Acad. Sci. 1112: 339-350.
31. Lewis, R.S. 2001. Calcium signaling mechanisms in T lymphocytes. Annu. Rev. Immunol. 19: 497-521.
32. Wen, B.G., M.T. Pletcher, M. Warashina, et al. 2004. Inositol (1,4,5) trisphosphate 3 kinase B controls positive selection of T cells and modulates Erk activity. Proc.Natl. Acad. Sci. USA 101: 5604-5609.
33. Tao, L., R.H. Wang, S.A. Enkemann, et al. 1999. Metabolic regulation of protein-bound glutamyl phosphates: insights into the function of prothymosin α. J. Cell. Physiol. 178: 154-163.
34. Gómez-Márquez, J. 2007. Function of prothymosin alpha in chromatin decondensation and expression of thymosin beta-4 linked to angiogenesis and synaptic plasticity. Ann. N.Y. Acad. Sci. 1112: 201-209.
35. Rot, A. & U.H. von Andrian. 2004. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22: 891-892.
36. Clare, L.A. & C.A. Lowell. 2009. The ins and outs of leukocyte integrin signaling. Annu. Rev. Immunol. 27: 339-362.
37. Pribila, J.T., A.C. Quale, K.L. Mueller & Y. Shimizu. 2004. Integrins and t cell-mediated immunity. Annu. Rev. Immunol. 22: 157-180.
38. Hunt, S.W., 3rd, E.S. Harris, S.A. Kellermann & Y. Shimizu. 1996. T-lymphocyte interactions with endothelium and extracellular matrix. Crit. Rev. Oral Biol. Med. 7: 59-86.
39. Kawai, T. & S. Akira. 2009. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 21: 317-337.
40. Geijtenbeek, T.B.H. & S.I. Gringhuis. 2009. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 9: 465-479.
41. Kolls, J.K., P.B.McCray Jr. & Y.R. Chan. 2008. Cytokinemediated regulation of antimicrobial proteins. Nat. Rev. Immunol. 8: 829-833.
42. Ip, W.K., K. Takahashi, R.A. Ezekowitz & L.M. Stuart. 2009. Mannose-binding lectin and innateimmunity. Immunol. Rev. 230: 9-21.
43. Romani, L., F. Bistoni, R. Gaziano, et al. 2004. Thymosin alpha-1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 103: 4232-4239.
44. Bozza, S., R. Gaziano, P. Bonifazi, et al. 2007. Thymosin alpha1 activates the TLR9/MyD88/IRF7- dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. Int. Immunol. 19: 1261-1270.
45. Dinarello, C.A. 2009. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27: 519-550.
46. Chambers,C.A., S. Gallinger, S.K. Anderson, et al. 1994. Expression of the NK-TR gene is required for NK-like activity in human T cells. J. Immunol. 152: 2669-2674.
47. Gunturi, A., R.E. Berg & J. Forman. 2004. The role of CD94/NKG2 in innate and adaptive immunity. Immunol. Res. 30: 29-34.
48. Huntington, N.D., N. Legrand, N.L. Alves, et al. 2009. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J. Exp. Med. 206: 25-34.
49. Giuliani, C., G. Napoletano, A. Mastino, et al. 2000. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur. J. Immunol. 30: 778-786.
50. Binder, R.J., R. Vatner & P. Srivastava. 2004. The heatshock protein receptors: some answers and more questions. Tissue Antigens 64: 442-451.
51. Multhoff, G. 2007.Heat shock protein 70 (Hsp70):membrane location, export and immunological relevance. Method 43: 229-237.
52. Multhoff, G. 2009. Activation of natural killer cells by heat shock protein 70 (Review 2002). Int. J. Hyperthermia 25: 169-175.
53. Naylor, P.H. & J.W. Hadden. 2003. T cell targeted immune enhancement yields effective T cell adjuvants. Int. Immunopharmacol. 3: 1205-1215.
54. Naylor, P.H., K. Quadrini, E. Garaci, et al. 2007. Immunopharmacology of thymosin α1 and cytokine synergy. Ann. N.Y. Acad. Sci. 1112: 235-244.
55. Goldstein, A.L. & E. Garaci. 1992. Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases
56. Garaci, E. & A.L. Goldstein. 1993. Combination Therapies II: Biological Response Modifiers in the Treatment of Cancer and Infectious Disease, Plenum Press, New York.
57. Garaci, E., F. Pica, G. Rasi, et al. 1997. Combination therapy with BRMs in cancer and infectious diseases. Mech. Ageing Dev. 96: 103-116.